- ￥1800
- EK-Bioscience
- 国内
- MY-K5574
- 2026年01月04日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 英文名：
NCI-H2087
- 库存：
1x10^6/瓶/支
- 供应商：
上海酶研
- 肿瘤类型：
无
- 细胞类型：
人非小细胞肺腺癌细胞
- ATCC Number：
详询
- 品系：
NCI-H2087
- 组织来源：
人非小细胞肺腺癌细胞
- 相关疾病：
NCI-H2087
- 物种来源：
哺乳动物
- 免疫类型：
详询
- 细胞形态：
贴壁/悬浮
- 是否是肿瘤细胞：
详询
- 器官来源：
人非小细胞肺腺癌细胞
- 运输方式：
顺丰快递
- 年限：
5年
- 生长状态：
生长良好
NCI-H2087/NCI-H2087细胞系/NCI-H2087细胞株/NCI-H2087人非小细胞肺腺癌细胞
Cell line name NCI-H2087
Synonyms H2087; H-2087; NCIH2087
Accession CVCL_1524
Resource Identification Initiative To cite this cell line use: NCI-H2087 (RRID:CVCL_1524)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Population: Caucasian.
Doubling time: 51 hours (PubMed=29681454); ~52 hours (PBCF).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Array-based CGH.
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
PubMed=12068308; DOI=10.1038/nature00766
Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)
PubMed=16157194; DOI=10.1016/j.cancergencyto.2005.03.007
Grigorova M., Lyman R.C., Caldas C., Edwards P.A.W.
Chromosome abnormalities in 10 lung cancer cell lines of the NCI-H series analyzed with spectral karyotyping.
Cancer Genet. Cytogenet. 162:1-9(2005)
PubMed=16187286; DOI=10.1002/ijc.21491
Garnis C., Lockwood W.W., Vucic E., Ge Y., Girard L., Minna J.D., Gazdar A.F., Lam S., MacAulay C., Lam W.L.
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH.
Int. J. Cancer 118:1556-1564(2006)
PubMed=18397470; DOI=10.1111/j.1749-0774.2008.00046.x
Ueda M., Toji E., Nunobiki O., Izuma S., Okamoto Y., Torii K., Noda S.
Mutational analysis of the BRAF gene in human tumor cells.
Hum. Cell 21:13-17(2008)
PubMed=19472407; DOI=10.1002/humu.21028; PMCID=PMC2900846
Blanco R., Iwakawa R., Tang M.-Y., Kohno T., Angulo B., Pio R., Montuenga L.M., Minna J.D., Yokota J., Sanchez-Cespedes M.
A gene-alteration profile of human lung cancer cell lines.
Hum. Mutat. 30:1199-1206(2009)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=20557307; DOI=10.1111/j.1349-7006.2010.01622.x; PMCID=PMC11158680
Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J.
Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma.
Cancer Sci. 101:1891-1896(2010)
PubMed=20679594; DOI=10.1093/jnci/djq279; PMCID=PMC2935474
Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.
Lung cancer cell lines as tools for biomedical discovery and research.
J. Natl. Cancer Inst. 102:1310-1321(2010)
PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
重大突破！甘波谊团队 Nature 首次报道第三种铁死亡抑制机制，提供抗癌新思路
）使细胞对 GPX4 抑制剂更加敏感；然而，添加尿苷并不影响细胞对 GPX4 抑制剂的敏感性。 图片来源：NatureDHO 和 OA 分别是 DHODH 反应的底物和产物，DHO 和 OA 对铁死亡有着相反的影响，提示 DHODH 可能对于铁死亡有着调节作用。作者发现抑制 DHODH 可诱导 GPX4 低表达的细胞（如 NCI-H226）发生铁死亡；对于 GPX4 高表达的细胞（如 HT-1080），抑制 DHODH 不能显著诱导铁死亡的发生，但能使细胞对铁死亡诱导剂变得更加敏感，而敲除 GPX
真爱满行囊 我最近在体外细胞做的关于gsk3-beta功能问题，发现药物处理以后，gsk-3-beta的总表达量下调，如果是这样的话 1、我是否能够得出gsk-3-beta的活性下调的结论？ 2、是否还有必要做非活性形式的表达量？我的理解是，基础状态下，gsk-3beta维持的是低活性状态，如果总量都下调了，那应该能够得出活性降低的结论了吧？ 3、另外，在这种情况下我是否有必要去做gsk-3-beta的216位点的活性形式的表达
表观遗传是指 DNA 序列不发生变化但基因表达却发生了可遗传的改变，即基因型未发生变化而表型却发生了改变。换言之，这是一种 DNA 序列外的遗传方式。因素如 DNA 甲基化、组蛋白修饰和 miRNA 是对环境刺激因素变化的反映，这些表观遗传学因素相互作用以调节基因表达，控制细胞表型，所有这些表观遗传学因素都是维持机体内环境稳定所必需的，有助于正常生理功能的发挥。 组蛋白的翻译后修饰不仅与染色体的重塑和功能紧密相关，而且在决定细胞命运、细胞生长以及致癌作用的过程中发挥着重要的作用，如组
技术资料